RBC Capital Maintains Outperform on Nurix Therapeutics, Lowers Price Target to $26

Benzinga · 10/14 13:43
RBC Capital analyst Gregory Renza maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and lowers the price target from $27 to $26.